Blood-pressure lowering in intermediate-risk persons without cardiovascular disease

Antihypertensive therapy reduces the risk of cardiovascular events among high-risk persons and among those with a systolic blood pressure of 160 mm Hg or higher,but its role in persons at intermediate risk and with lower blood pressure is unclear In one comparison from a 2-by-2 factorial trial, w...

Full description

Bibliographic Details
Main Authors:	Lonn, Eva M., Bosch, Jackie, López‑Jaramillo, Patricio, Jun, Zhu, Lisheng, Liu, Pais, Prem, Md Aris, Mohd Aznan, Mohd Shah, Azarisman Shah, ., et. al
Format:	Article
Language:	English English
Published:	Massachusetts Medical Society 2016
Subjects:	R Medicine (General) RC Internal medicine RJ Pediatrics RZ Other systems of medicine
Online Access:	http://irep.iium.edu.my/50354/ http://irep.iium.edu.my/50354/ http://irep.iium.edu.my/50354/ http://irep.iium.edu.my/50354/1/Blood-Pressure_Lowering_in_Intermediate-.pdf http://irep.iium.edu.my/50354/2/DR_AZNAN.pdf

id	iium-50354
recordtype	eprints
spelling	iium-503542018-05-22T03:24:11Z http://irep.iium.edu.my/50354/ Blood-pressure lowering in intermediate-risk persons without cardiovascular disease Lonn, Eva M. Bosch, Jackie López‑Jaramillo, Patricio Jun, Zhu Lisheng, Liu Pais, Prem Md Aris, Mohd Aznan Mohd Shah, Azarisman Shah ., et. al R Medicine (General) RC Internal medicine RJ Pediatrics RZ Other systems of medicine Antihypertensive therapy reduces the risk of cardiovascular events among high-risk persons and among those with a systolic blood pressure of 160 mm Hg or higher,but its role in persons at intermediate risk and with lower blood pressure is unclear In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants at intermediate risk who did not have cardiovascular disease to receive either candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a dose of 12.5 mg per day or placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke; the second coprimary outcome additionally included resuscitated cardiac arrest, heart failure, and revascularization. The median follow-up was 5.6 years. Massachusetts Medical Society 2016-05-26 Article PeerReviewed application/pdf en http://irep.iium.edu.my/50354/1/Blood-Pressure_Lowering_in_Intermediate-.pdf application/pdf en http://irep.iium.edu.my/50354/2/DR_AZNAN.pdf Lonn, Eva M. and Bosch, Jackie and López‑Jaramillo, Patricio and Jun, Zhu and Lisheng, Liu and Pais, Prem and Md Aris, Mohd Aznan and Mohd Shah, Azarisman Shah and ., et. al (2016) Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. New England Journal of Medicine, 374 (21). pp. 2009-2020. ISSN 0028-4793 E-ISSN 1533-4406 htpp://www.nejm.org.com 10.1056/NEJMoa1600175
repository_type	Digital Repository
institution_category	Local University
institution	International Islamic University Malaysia
building	IIUM Repository
collection	Online Access
language	English English
topic	R Medicine (General) RC Internal medicine RJ Pediatrics RZ Other systems of medicine
spellingShingle	R Medicine (General) RC Internal medicine RJ Pediatrics RZ Other systems of medicine Lonn, Eva M. Bosch, Jackie López‑Jaramillo, Patricio Jun, Zhu Lisheng, Liu Pais, Prem Md Aris, Mohd Aznan Mohd Shah, Azarisman Shah ., et. al Blood-pressure lowering in intermediate-risk persons without cardiovascular disease
description	Antihypertensive therapy reduces the risk of cardiovascular events among high-risk persons and among those with a systolic blood pressure of 160 mm Hg or higher,but its role in persons at intermediate risk and with lower blood pressure is unclear In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants at intermediate risk who did not have cardiovascular disease to receive either candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a dose of 12.5 mg per day or placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke; the second coprimary outcome additionally included resuscitated cardiac arrest, heart failure, and revascularization. The median follow-up was 5.6 years.
format	Article
author	Lonn, Eva M. Bosch, Jackie López‑Jaramillo, Patricio Jun, Zhu Lisheng, Liu Pais, Prem Md Aris, Mohd Aznan Mohd Shah, Azarisman Shah ., et. al
author_facet	Lonn, Eva M. Bosch, Jackie López‑Jaramillo, Patricio Jun, Zhu Lisheng, Liu Pais, Prem Md Aris, Mohd Aznan Mohd Shah, Azarisman Shah ., et. al
author_sort	Lonn, Eva M.
title	Blood-pressure lowering in intermediate-risk persons without cardiovascular disease
title_short	Blood-pressure lowering in intermediate-risk persons without cardiovascular disease
title_full	Blood-pressure lowering in intermediate-risk persons without cardiovascular disease
title_fullStr	Blood-pressure lowering in intermediate-risk persons without cardiovascular disease
title_full_unstemmed	Blood-pressure lowering in intermediate-risk persons without cardiovascular disease
title_sort	blood-pressure lowering in intermediate-risk persons without cardiovascular disease
publisher	Massachusetts Medical Society
publishDate	2016
url	http://irep.iium.edu.my/50354/ http://irep.iium.edu.my/50354/ http://irep.iium.edu.my/50354/ http://irep.iium.edu.my/50354/1/Blood-Pressure_Lowering_in_Intermediate-.pdf http://irep.iium.edu.my/50354/2/DR_AZNAN.pdf
first_indexed	2023-09-18T21:11:10Z
last_indexed	2023-09-18T21:11:10Z
_version_	1777411261965795328

Blood-pressure lowering in intermediate-risk persons without cardiovascular disease

Similar Items